111 results
Page 4 of 6
6-K
EX-99.1
ueiffsmxz6utjxwvh6k
4 Dec 14
Live Filing
12:00am
6-K
EX-99.1
dhor9ac rnqmcq27t
1 Dec 14
Teva Announces Launch of Generic Exforge HCT® Tablets In the United States
12:00am
6-K
EX-99.1
1oc7shy
1 Dec 14
Live Filing
12:00am
6-K
EX-99.1
x21lq6uw13qhq9 54nr
26 Nov 14
Prof. Yitzhak Peterburg Elected Chairman of Teva’s Board of Directors
12:00am
6-K
EX-99.1
zj558g04f vnq
18 Nov 14
Live Filing
12:00am
6-K
EX-99.1
5rj2wy
7 Nov 14
Late Stage Data to be Presented at ACAAI 2014
12:00am
6-K
EX-99.1
ixm22lza5da7dr0423l
7 Nov 14
Live Filing
12:00am
6-K
mxuob6uemyqyj1y7wia
30 Oct 14
Current report (foreign)
12:00am
6-K
EX-99.1
nh8uelwbiov0b03e9
30 Oct 14
Teva Reports Third Quarter 2014 Results
12:00am
6-K
EX-99.1
i3tdg6j8 jiy1b0k
8 Oct 14
Live Filing
12:00am
6-K
EX-99.1
8nas7kz6ajx40
6 Oct 14
Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas
12:00am
6-K
EX-99.1
7dbumr my5i
12 Sep 14
Teva Presents Gene Expression Analysis at Joint ACTRIMS-ECTRIMS Meeting Demonstrating COPAXONE® (glatiramer acetate injection) Has a Complex Profile
12:00am
6-K
EX-99.1
v0rsurx9wnc f8c3d24x
12 Sep 14
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
12:00am
6-K
EX-99.1
euu5op ft
11 Sep 14
Live Filing
12:00am
6-K
EX-99.1
nmd11f
8 Sep 14
Successful Completion of Phase Iii Program for Teva’s Reslizumab
12:00am
6-K
EX-99.1
9skzx9im
4 Sep 14
Teva Announces Launch of Generic Baraclude® TABLETS,0.5MG and 1MG, In the United States
12:00am
6-K
EX-99.1
zvmy12t3rvd40
3 Sep 14
Teva Launches Syncaretm Home Administration Support Program for Patients on Synribo® (Omacetaxine Mepesuccinate) for Injection
12:00am
6-K
EX-99.1
4xvmmaaubllle31tq37
3 Sep 14
Live Filing
12:00am
6-K
EX-99.1
mpv3js bj9
3 Sep 14
Teva Announces UK High Court Gives Positive Judgment in the Company’s Patent Case Against AstraZeneca
12:00am
6-K
EX-99.1
j5wzws0rn
2 Sep 14
Live Filing
12:00am